Switching off cancer genes

Written on the 13 May 2009

 
PROGEN Pharmaceuticals is making progress in a technology aiming to ‘switch off’ cancerous genes. 
A pre-clinical study found that Progen’s epigenetic technology is able to inhibit tumour-suppressing enzymes. CEO Justus Homburg is excited about the results.
“In epigenetics we try to switch genes to change how that cell behaves, how to stop it being cancerous rather than saying cancer cells are bad and let’s kill them off — it represents a big shift in the paradigm and that’s why epigenetics is so exciting,” explains Homburg.
But drug development is a lengthy process and Homburg predicts it could be another six years before the product PG11144 is fully developed and on the market as the first, second and third phases of trials still need to be carried out.
“Could it be a long term development? Yes, that could very well be the case, but it’s something well worth pursuing because it is a dramatic change,” he says.
Homburg points out the very risky nature of the drug development industry but he believes the technology’s potential is backed up by the data that shows it does have an effect on tumours.
“We think there’s an opportunity out there, but the vast majority of drug developments don’t succeed,” he says.
“We may be only able to target a specific cancer or a specific disease of a specific cancer – there’s a lot to learn but it’s potentially quite groundbreaking.”
Homburg is confident that Progen is in a good financial position and is comfortable with the company’s patent on the technology.
“One of the things to bear in mind is that we’ve been through a lot of corporate turmoil, but we have been able to put an awful lot of that behind ourselves and during that time pursued research in all of our products,” he says.
“These latest findings prove we have the technology, the expertise and the resources to progress our strong product pipeline.”

Latest News

BABY STEPS FOR BELLAMY'S IN TURNAROUND

GREEN shoots are appearing in the Bellamy's Organic (ASX: BAL) business in the early days of its turnaround.

T...

LOSSES MOUNT AT SLATER AND GORDON

SLATER and Gordon's losses continue to mount following its disastrous entry in to the UK market. The compa...

NVC PLAYS A DIFFERENT GAME, AND WINS

AS its profits rise, National Veterinary Care's (ASX: NVL) focus on training over retail is proving to be a wi...

SUPERLOOP $2M LOSS DOES LITTLE TO KILL SLATTERY'S CONFIDENCE

BEVAN Slattery (pictured) is optimistic that Superloop's (ASX: SLC) financial position is promising, despite t...

Related News

HOW TO TAKE CONTROL OF YOUR CAREER THROUGH TRAINING

GIG economy, remote working, and freelance Friday are more than just buzz terms; our workforce is changing, and so...

EVERYTHING YOU NEED TO KNOW ABOUT THE NATIONAL BROADBAND NETWORK

THE National Broadband Network (NBN) is more than an internet connection, it is an opportunity to transform your b...

WHY EMPLOYEE-OWNED COMPANIES ARE BEATING ASX200 SHARE PRICES

EMPLOYEE-owned companies command a higher share price than their publicly listed peers, reaping a 17 per cent prem...

RISE OF THE MACHINES HAS WORKERS SWEATING

UP TO 3.8 million Australian workers are fearful their job may soon be terminated by a robot, a new survey has shown....

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter